Health risk assessments shed light on early predictors of depression

Johnson & JohnsonA new research study supported by Johnson & Johnson Health and Wellness Solutions suggests that health risk assessments (HRAs) can help predict depression in segments of the population who may not be routinely screened in traditional healthcare settings. HRAs are often used by employers and health plans to identify modifiable health risks, such as stress, sleep and quality of life. This new study demonstrates the value of HRAs to identify predictors for depression.

The research study found that about 25 percent of the HRA participants experienced mild or "sub-threshold" symptoms of depression. One in five of them deteriorated over time to more significant distress, as measured by an increase in symptoms of depression. These individuals had a similar level of symptoms as individuals with chronic depression at the end of the study and experienced an even greater level of functional impairment in their day to day lives. The study also identified key risk factors that predicted both positive and negative changes in depressive symptoms. As employers look for ways to increase the health and productivity of their employees, the value of further research using HRAs to study populations at risk for depression is notable.

"This study indicates that HRAs can be a useful and powerful analytic tool to identify and begin early intervention for at-risk populations," said Heather Cole-Lewis, PhD, Behavioral Scientist, Johnson & Johnson Health and Wellness Solutions. "There is a substantial group of people among our HRA participants who have depressive symptoms but might not necessarily meet criteria indicating a need for clinical management. We know now that a significant portion of them are at risk of progressing to levels of distress and experiencing considerable productivity impairment in the process. We need to find ways to reach these individuals before they experience such difficulties."

Symptoms of depression have been shown to decrease daily function and productivity, and play a significant role in determining the success of population health management efforts. Given that 53 percent of large U.S. employers and 23 percent of small U.S. employers use HRAs with employees, the opportunity for further longitudinal data analysis in large populations is compelling and has the potential to facilitate earlier interventions for preventing depression.

"HRAs have been used for a long time to look at the health information for populations at large. One of the most useful takeaways from this study is that HRAs can help identify individuals with subthreshold depressive symptoms who may deteriorate over time, as well as those who are at risk of chronic depression," said Jennifer Turgiss, Vice President, Behavioral Science & Advanced Analytics, Johnson & Johnson Health and Wellness Solutions. "We at Johnson & Johnson recommend that health plan providers, including self-insured employers, consider using HRAs to help identify subthreshold individuals and explore new methods to reach them as early as possible with solutions that build important skills, such as resilience, to help manage and improve low-levels of depression."

About the Study
The study, "Trajectories of Depressive Symptoms among Online Health Risk Assessment Participants," was published in the Journal of Medical Internet Research on March 31, 2017. It was conducted by Johnson & Johnson Health and Wellness Solutions as part of the company's commitment to health and wellbeing. The study used data collected from the online HRAs of 22,963 adult participants.

The study used a growth mixture model to examine longitudinal trends in depressive symptoms of voluntary HRA adult participants. The study identified five classes of depressive symptom trajectories: "minimal depression" (scores were consistently low across time), "low risk" (scores remained sub-threshold over time), "deteriorating" (scores began at sub-threshold but approached severe depression over time), "chronic" (scores remained in highly depressive category over time) and "remitting" (moderate depression to start but crossed into minimal by the end).

About Johnson & Johnson Health and Wellness Solutions
Johnson & Johnson Health and Wellness Solutions, Inc. serves as the center of excellence for Johnson & Johnson's capabilities in behavior modification, patient/consumer experience, health care analytics and coaching platforms. It offers an integrated portfolio of solutions to cover a broad spectrum of health management - from wellness and prevention, to behavioral health, to chronic disease support. These solutions are designed to improve outcomes, control costs and enhance the patient and consumer experience. Its guiding purpose is to invest energy toward vibrant and longer lives.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]